Objective To analyse clinical value of PET/CT. Methods Data of 605 cases were collected and final diagnosis was confirmed by puncture biopsy, imaging examination and follow-up results. GE MINItrace and TracerLab were used to automatically produce 18F-FDG. GE Discovery STE was PET/CT scanner. Injection dose of 18F-FDG was 0. 12 mCi · kg-1 and 2D acquisition was performed 60 minutes after injection (3 minutes per bed,from the head to the groin). Results Of the 605 cases, the presence of tumor was suspected or confirmed in 548 (90. 6%). A-mong them, the diagnosis or investigation of malignant tumors was performed in 299,preopera-tive tumor staging in 75 , tumor recurrence estimation in 67 , efficacy evaluation of radiotherapy and chemotherapy in 59,and primary tumor search in 48. Of the 52 healthy subjects (8. 6%) of the 605 cases,malignant lesions were found in 3 and nervous system disease in 5 (4 cases of epilepsy and 1 case of Alzheimer disease). No cases had cardiac disease. Conclusion PET/CT can reveal characteristics of functional imaging and anatomical imaging and has obvious advantages in early detection of tumors, differential diagnosis of benign and malignant tumors, primary tumor search, clinical staging, efficacy evaluation, tumor recurrence estimation and re-staging, biopsy localization, interventional therapy,and formulation of radiation scheme.%目的 分析PET/CT的临床应用价值.方法结合穿刺活检、多种影像学检查和临床随访结果对605例PET/CT受检者进行诊断.PET/CT为GE Discovery STE,18F-FDG由GE MINItrace生产和全自动化学方法合成,注射剂量为0.12 mCi·kg-1,注药 60 min后以 3 min·床位-1进行2D扫描,扫描范围为头部至腹股沟下.结果 605例受检者中,临床怀疑或已确诊的肿瘤患者548例,占90.6%(548/605),其中用于恶性肿瘤诊断或排查299例、治疗前肿瘤分期75例、肿瘤术后复发判断67例、肿瘤放化疗疗效评估59例、原发灶寻找48例;健康体检者52例,占8.6%(52/605),其中3例检出恶性病变,占5.7%(3/52);神经系统疾病者5例(其中4例为癫,1例为阿尔默海兹病),占0.8%(5/605);无心脏疾病受检者.结论 PET/CT结合了功能显像和解剖显像的特点,在肿瘤的早期发现、良恶性肿瘤的鉴别诊断、原发灶寻找、临床分期、疗效评估、肿瘤复发判断及再分期、活检定位以及介入治疗与放射计划的制定等方面优势明显.
展开▼
